Sonoma Pharmaceuticals shares surge 24.04% after-hours on 22% Q3 revenue growth and improved EBITDAS.

Sonoma Pharmaceuticals (SNOA) surged 24.04% in after-hours trading following the release of its third fiscal quarter and nine-month financial results for the period ended December 31, 2025. The company reported a 22% year-over-year increase in Q3 revenue to $4.3 million and a 33% rise in nine-month revenue to $14.0 million, driven by strong U.S. sales growth in over-the-counter products and distributor expansion. Gross margin improved to 38% in Q3, and EBITDAS loss narrowed by $0.4 million in the quarter and $0.9 million for the nine months, reflecting cost management and operational efficiency. CEO Amy Trombly highlighted strategic progress, including regulatory advancements and leadership additions, reinforcing the company’s positioning in the hypochlorous acid market. The results underscored execution of growth priorities and reduced financial losses, fueling investor optimism.